title: Leishmaniasis in the United States: treatment in 2012.
abstract: Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.
authors.affiliation: Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA. hwmurray@med.cornell.edu
authors.forename: Henry W
authors.initials: HW
authors.lastname: Murray
mesh_terms: D000284:Administration, Oral; D000666:Amphotericin B / Q000008:administration & dosage; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007275:Injections, Intravenous / Q000379:methods; D007896:Leishmaniasis / Q000188:drug therapy* / Q000453:epidemiology*; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014481:United States / Q000453:epidemiology
chemical_list: D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B